<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>ozanimod &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/ozanimod/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 07 Oct 2026 04:51:41 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>ozanimod &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Stopping Ozanimod: Large Trial Follow-Up Finds Relapses Return Mildly, With No Sign of Rebound</title>
		<link>https://bioengineer.org/stopping-ozanimod-large-trial-follow-up-finds-relapses-return-mildly-with-no-sign-of-rebound/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 07 Oct 2026 04:51:41 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[DAYBREAK trial]]></category>
		<category><![CDATA[disease-modifying therapy]]></category>
		<category><![CDATA[fingolimod]]></category>
		<category><![CDATA[lymphocytes]]></category>
		<category><![CDATA[Multiple Sclerosis]]></category>
		<category><![CDATA[natalizumab]]></category>
		<category><![CDATA[neurology]]></category>
		<category><![CDATA[ozanimod]]></category>
		<category><![CDATA[Pharmacokinetics]]></category>
		<category><![CDATA[rebound]]></category>
		<category><![CDATA[relapse]]></category>
		<category><![CDATA[S1P receptor modulator]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=405217</guid>

					<description><![CDATA[A large post hoc analysis of the DAYBREAK trial found that only 3.3 percent of patients relapsed after stopping ozanimod, with episodes clustering two to three months later and no evidence of rebound disease activity.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">405217</post-id>	</item>
	</channel>
</rss>
